7,183 Shares in Danaher Corporation $DHR Purchased by Stokes Capital Advisors LLC

Stokes Capital Advisors LLC acquired a new stake in Danaher Corporation (NYSE:DHR) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 7,183 shares of the conglomerate’s stock, valued at approximately $1,591,000.

Several other hedge funds and other institutional investors have also made changes to their positions in DHR. Mirador Capital Partners LP grew its position in shares of Danaher by 28.4% in the 3rd quarter. Mirador Capital Partners LP now owns 29,355 shares of the conglomerate’s stock valued at $6,504,000 after acquiring an additional 6,492 shares during the period. Capital Advisors Wealth Management LLC acquired a new position in shares of Danaher during the 3rd quarter worth about $1,816,000. RFG Bristol Wealth Advisors LLC raised its holdings in shares of Danaher by 215.0% in the 3rd quarter. RFG Bristol Wealth Advisors LLC now owns 3,790 shares of the conglomerate’s stock valued at $840,000 after purchasing an additional 2,587 shares during the period. Biltmore Wealth Management LLC acquired a new stake in Danaher in the 3rd quarter valued at about $716,000. Finally, Sound Income Strategies LLC acquired a new stake in Danaher in the 3rd quarter valued at about $1,341,000. 79.05% of the stock is owned by institutional investors.

Danaher Trading Up 1.2%

Shares of DHR stock opened at $220.15 on Friday. Danaher Corporation has a 12-month low of $160.93 and a 12-month high of $242.80. The company has a market capitalization of $154.76 billion, a PE ratio of 39.10, a price-to-earnings-growth ratio of 2.71 and a beta of 0.76. The firm has a 50 day moving average price of $211.38 and a two-hundred day moving average price of $194.62. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48.

Danaher (NYSE:DHR) last announced its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. The company had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The firm’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.77 earnings per share. As a group, analysts predict that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.40 per share. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 annualized dividend and a yield of 0.7%. Danaher’s dividend payout ratio (DPR) is presently 28.42%.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Barclays boosted their price target on Danaher from $230.00 to $255.00 and gave the stock an “overweight” rating in a research report on Wednesday. Guggenheim lifted their target price on Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. UBS Group assumed coverage on Danaher in a report on Wednesday, September 9th. They set a “buy” rating and a $250.00 target price on the stock. Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, The Goldman Sachs Group raised their price target on Danaher from $210.00 to $250.00 and gave the company a “buy” rating in a report on Monday, September 21st. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $235.23.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.